AliveCor gets FDA nod for suite of cardiac focused AI algorithms

Cardio-focused digital health company AliveCor landed FDA clearance for its new suite of interpretive ECG algorithms, dubbed the Kardia AI V2. This news comes just days after the company announced a $65 million Series E funding round. The new clearance will is able to capture sinus rhythm with premature ventricular contractions, sinus rhythm with supraventricular ectopy and a sinus rhythm with wide QRS. The algorithm works on AliveCor's KardiaMobile and KardiaMobile 6L devices, which even before this latest FDA clearance, have been able to take 30-second ECGs, and are hooked up to a corresponding app. According to the company's release, the algorithm will also reduce the number of unclassified readings, and has improved sensitivity and specificity on the company's normal and atrial fibrillation algorithms. Users will also have new visualization tools that let them see heart beat average, PVC identification and tachogram.